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Introduction: The phenomenon of adherence to treatment is a motive of worry from the 
scientific community, since it is considered as a worldwide problem of high magnitude. 
The implications are of great relevance in morbidity, mortality, in the signiÀ cant increase in the 
consumption of health care and in the costs to the health system, particularly in patients with 
ischemic heart disease. We intend to evaluate adherence to treatment and relate beliefs about 
medicines with adherence to treatment.
Material and methods: This study is descriptive-correlational and cross-sectional. It was 
performed on 254 patients with ischemic heart disease who were in follow-up consultation in 
the hospital at the time of the questionnaire application. Data collection was performed 
through a self-administered questionnaire, integrating the following scales: Measure Adherence 
to Treatment and Beliefs about Medicines Questionnaire.
Results: The patients had a mean age of 66.94 years (SD = 11.62), 74% were male, 73.2% were 
married, 69.3% had education up to the “4th grade”, 57.1% lived in the village, 70.1% 
were retired and 49.6% had an income below “one minimum wage”. We found that 50.4% of 
patients did not adhere to treatment. Women had a strong belief in the speciÀ c needs of the 
prescribed medication, while men expressed greater belief in relation to long-term side effects 
(P > .05). Patients who expressed a low belief about the harmful potential of medicines revealed 
predictors of adherence to medication.
Conclusion: The results are consistent with previous studies in which individuals with lower 
beliefs in speciÀ c concerns reported higher rates of adherence to medication.
© 2014 Elsevier España, S.L. All rights reserved.
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Introduction
Cardiovascular disease (CVD) in Portugal, like in other 
developed countries, are the main cause of death (40% of 
global mortality and are one of the main causes of hospita-
lization and physical inability).1
Nowadays a signiÀ cant percentage of the world population 
is faced with the need to take medication and adopt 
measures to control and treat acute and chronic conditions. 
In chronic disease, the medication is often the À rst choice in 
the treatment of disease, being the most common health 
intervention.2
Despite the advances in patients’ treatment with ischemic 
heart disease, treatment regimens are beneficial only if 
patients adhere. Thus, low adherence to cardiovascular 
medication led to considerable morbidity, mortality and 
preventable health costs.2-4
The cardioprotective medication (antiplatelet agents, 
b-blockers, statins and/or angiotensin-converting enzyme 
inhibitors (ACEI)) was associated with the reduction of 
relative risk of mortality by acute coronary syndrome (ACS) 
in 80% compared to the treatment with placebo. In the 
United States of America, it is estimated that secondary 
prevention contributed to a 11% decrease in the number of 
deaths by ACS.2
In Portugal, the full adherence to medical prescriptions is 
about one third of the patients population undergoing 
treatment. However, 88% of the participants in this study 
responded that they follow the treatment properly.5
It is estimated that about 125,000 deaths per year in the 
United States of America are due to non-adherence to 
medication and between 33% and 69% of hospitalizations 
were due to low adherence.2
The non-adherence becomes an issue to be considered 
when we want quality of health care as well as cost 
containment and greater effectiveness of resources. Studies 
of secondary prevention of ACS showed a cost reduction 
around 10.1% to 17.8% among adherent and non-adherent 
patients, corresponding to 294 and 868 dolars per patient.6
The concept of adherence has been changing over time. 
Initially, this dimension was associated with prescription 
compliance, regarding the adoption of conducts coincident 
with medical indication in terms of medication and healthy 
behaviour. It has a connotation of obedience and an attitude 
of passivity, in which the responsibility of treatment failure 
falls on the person.
Nowadays, the concept of adherence is more compre hen-
sive and less reductionist. It implies an active involve ment by 
the person with the chronic condition, in a not imposed way, 
but mutually accepted, regarding planning, implementation 
and execution of a therapeutic regimen. There are several 
factors that interfere with adherence and that makes the 
responsibility is shared by the person (that act on), by health 
professionals (that enable and facilitate the action) and by 
the social context (in which the action unfolds). 
The WHO presented a report about adherence values in 
various medical conditions and concluded that the adhe-
rence to long-term treatment in the general population is 
about 50%, being much lower in the developing countries 
than in Western society.7
The medicines are the main tools used to effectively 
prevent and manage chronic disease. It is estimated that 
the cardioprotective medication is responsible for 50% 
reduction in mortality for ACS in the last 20 years.2-4
Several studies showed that beliefs about medicines can 
be a barrier to adherence.8 Thus, patients have their own 
perspectives on the use of medication and make decisions 
based on their beliefs and experiences. They weigh the risks 
and beneÀ ts relating to medication and they conclude their 
judgments, taking into account the perceived effectiveness, 
safety and value in terms of outcomes for their health.9-11
The beliefs about the behaviour are as important as the 
beliefs about the disease in predicting various behaviours 
related to health. This suggests the possibility that the 
interventions of change behaviour with groups of patient 
would be more effective, targeting beliefs about the 
behaviour, instead of the beliefs about the disease. However, 
several authors referred that prospective studies about the 
impact of perceptions of the disease and adherence to 
secondary prevention in patients with CVD are scarce.12 
Thus, we intend to evaluate adherence to treatment and 
relate the inÁ uence of beliefs about medicines on adherence 
to treatment.
Material and methods
This is a descriptive-correlational and cross-sectional study. 
We selected 254 patients with ischemic heart disease who 
were in follow-up consultation in the hospital at the time of 
the questionnaire application. The inclusion criteria were: 
a) older than 18 years; b) physician diagnosis of acute 
myocardial infarction (AMI) or unstable angina for at least six 
months; and c) agree to participate in the study, expressed 
in the consent form.
Patients with a diagnosis of psychiatric disorder and 
institutionalized patients were excluded.
Data collection was performed through a self-administered 
questionnaire, integrating:
—  Sociodemographic variables (sex, age, marital status, 
residential area, education level, employment status and 
monthly household income);
—  Scale of Measure Treatment Adherence (MTA)13 used to 
evaluate adherence to treatment. The items 1 to 4 were 
adapted from Morisky Medication Adherence Scale. The 
questions were answered in six-point Likert scale (ranging 
from always = 1 to never = 6). The level of adherence is 
obtained through the mean. Higher values mean higher 
adherence level. In order to classify patients that showed 
adherence or not to treatment with medicines, this scale 
was dichotomized based on the cut-off point at the median.
—  Beliefs about Medicines Questionnaire (BMQ)14 that 
evaluates patients’ beliefs about medication. We used 
BMQ-SpeciÀ c that assesses the cognitive representations 
that individuals make in relation to medicines for their 
speciÀ c health problem. The questionnaire consists of 
two scales: one assessing necessity of prescribed medica-
tions and other assessing concerns about potential 
adverse consequences of taking the medications.
We made the psychometric study of MTA and BMQ-SpeciÀ c. 
The reliability was veriÀ ed by the Cronbach’s alpha and 
coefÀ cient of bipartition (split-half). To validate the construct 
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we used the factor analysis of the items, preceded by the 
Kaiser-Meyer-Olkin test.
With the descriptive statistic we determined frequencies 
and percentages, means, standard deviation and chi-square. 
The Mann-Whitney U test was used instead of student’s 
t-test when the groups are not similar in size.15 We also used 
multiple linear regression by stepwise method.
In the statistical analysis, we used SPSS (Statistical Package 
for the Social Sciences) version 20.0 for Windows. 
The research protocol was evaluated and approved by the 
Ethic Committee and the informed consent statement was 
obtained from all the participants.
Results
The patients had a mean age of 66.94 years (SD = 11.62), 74% 
were male, 73.2% were married, 69.3% had education up to 
the “4th grade”, 57.1% lived in the village, 70.1% were 
retired, 49.6% had an income below “one minimum wage” and 
51.6% reported having some economic difÀ culties (Table 1).
The majority of patients (50,4%) did not adhere to treat-
ment and men adhered less than women (53.2% vs. 57.6%; 
P = .132).
We have found that the value relative to patients’ beliefs 
about the speciÀ c needs of the prescribed medication varies 
between 15 and 25, corresponding to a mean of 20.78 
(SD = 2.31). The speciÀ c concerns dimension evaluates the 
beliefs related to the dangers of dependence and toxicity or 
long-term side effects. This ranged between 5 and 24, which 
corresponds to a mean of 14.37 (SD = 3.42).
Women had a strong belief in the speciÀ c needs of the 
prescribed medication, while men expressed greater belief 
in concerns, but without statistical signiÀ cance
To check the effect of beliefs about medicines in 
adherence to treatment, we found a very low correlation 
in the speciÀ c needs (r = î0.014; P = .830) and moderate in 
speciÀ c concerns (r = î0.367; P = .000). Moreover, we noted 
that the beliefs establish inverse relationships, being only 
signiÀ cant for the speciÀ c concerns dimension.
Through multiple linear regression by stepwise method, 
we identiÀ ed a prediction model in which only the speciÀ c 
Table 1 Socio-demographic characteristics
Male (n = 188) Female (n = 66) Total (n = 254) x2 (P)
 N % N % N %  
Age group
 ≤ 55 old 40 21.3 10 15.2 50 19.7 x2 = 19.120
 56-65 old 50 26.6 4 6.1 54 21.3 P = .000a
 66-75 old 54 28.7 22 33.3 76 29.9
 ≥ 76 old 44 23.4 30 45.5 74 29.1
Marital status    
 Single/widowed/divorced 40 21.3 28 42.4 68 26.8 x2 = 11.144
 Married 148 78.7 38 57.6 186 73.2 P = .001a
Education level    
 ≤ 4 old 124 66 52 78.8 176 69.3 x2 = 5.810
 5 a 12 old 50 26.6 8 12.1 58 22.8 P = .055 nsb
 > 12 old 14 7.4 6 9.1 20 7.9
Employment status    
 Employee 52 27.7 6 9.1 58 22.8 x2 = 12.3484
 Unemployed 12 6.4 2 3 14 5.5 P = .006a
 Sick leave 2 1.1 2 2 4 1.6
 Retired 122 64.9 56 84.8 178 70.1
Monthly household income    
 ≤ 1 minimum wage 82 43.6 44 66.7 126 49.6 x2 = 13.407
 Between 1 a 2 minimum wages 60 31.9 14 21.2 74 29.1 P = .004a
 > 2 minimum wages 38 20.2 4 6.1 42 16.5
Financial status    
 Comfortable 26 13.8 6 9.1 32 12.6 x2 = 4.754
 Have enough for the needs 40 21.3 16 24.2 56 22.0 P = .191 nsb
 Has some difÀ culties 100 53.2 30 45.5 130 51.6
 It is very problematic 22 11.7 14 21.2 36 14.2
a P < .05.
b P >.05. 
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concerns dimension emerged as a signiÀ cant predictor of 
adherence to treatment (t = î6.267; P = .000). This model 
explains a variation of 13.5% (Table 2).
Discussion
Define and evaluate adherence to medicines remains a 
persistent challenge in research without actual consent.16 
Low adherence to cardioprotective medication is common 
in clinical practice and is associated to a wide range of 
adverse outcomes.6,17,18 In our study, only 49.6% of people 
with ischemic heart disease adhere to the prescribed 
medication.
Several studies using Morisky Medication Adherence Scale 
showed similar results to ours with 56% of participants 
classiÀ ed as adherents.18 Others studies reported slightly 
higher rates of adherence (66%).17 And still others studies 
had low rates, varying between 31-58% in adherence to 
prescribed cardioprotective medication (statins, b-blockers) 
with prevalence decline over time.18
In a randomized controlled study “Post-Myocardial 
Infarction Free Rx Event and Economic Evaluation (MI 
FREEE)” conducted with 5855 patients with AMI, the rates of 
adherence to cardioprotective medication were low, ranging 
from 36% to 49%, being 35.9% for ACEI, 45% for b-blockers, 
49% for statins, and 38.9% for this three medicines together.19
Another randomized multicentre study “Future Revascu-
larization Evaluation in Patients with Diabetes Mellitus: 
Optimal Management of Multivessel Disease (FREEDOM)”, 
recently presented at the American Heart Association 
congress in 2012, which included 2000 patients with 
multivessel disease and diabetes mellitus, concluded that 
only 20% of patients were taking the prescribed medication. 
These results have been replicated in other studies, 
particularly Bypass Angioplasty Revascularization Inves-
tigation (BARI-2D). 20
In our investigation, patients’ beliefs about the speciÀ c 
needs of the prescribed medication obtained a mean score 
of 20.78 (SD = 2.31) and in relation to the beliefs related to 
concerns, the mean was 14.37 (SD = 3.24). Only the speciÀ c 
concerns emerged as a signiÀ cant predictor of adherence to 
treatment. Thus, the lower the patients’ belief about the 
concerns, the greater is the adherence to medicines.
Several researches have shown that patients with stronger 
beliefs in the specific concerns recorded a lower rate of 
adherence to treatment, particularly in chronic diseases,21 
in heart failure,22 in diabetes, 23 in hyperlipidemia,24,25 in 
asthma,26 and in primary healthcare.27
A randomized prospective study showed similar results in 
that the non-adherent patients reported higher concern 
about their antihypertensive medicines than adherent 
patients. On the other hand, the negative beliefs about 
needs of the prescribed medication may contribute to an 
apathetic attitude leading to intended non-adherence.28
A longitudinal study, carried out in 309 elderly patients 
with high morbidity, concluded that beliefs about the 
specific needs of the prescribed medication predicted 
adherence to treatment (regardless of the intentionality to 
adhere or not).29
The explanation may be linked to individual beliefs about 
the specific needs of medication that enhances the 
adherence and the specific concerns about medication 
appear to play a minor role. However, several authors have 
pointed out that individual perceptions about the effective-
ness of medicines are crucial for understanding the 
adherence. This is even more emphasized by the fact that 
these beliefs are particularly important in elderly patients 
with multiple diseases, polymedicated and with complex 
medication schemes.26
The relative importance of cognitions about the speciÀ c 
needs suggests that patients improve adherence behaviour, 
if they are told that the medication suits their needs and 
allows them to control the course of their illness.
Another aspect reports to the patient proÀ le regarding 
previous behaviours face to adherence to medication. 
A study performed on 1433 patients with CVD revealed that 
among health beliefs, the most related factor to the statins 
adherence was behavioural intention.25
Another study reinforces the evidence that the decision of 
diabetic patients to selectively renounce some medicines 
because of the cost, is not inÁ uenced by economic factors, 
but by other factors such as beliefs and satisfaction with the 
information related to the medication.30
Low adherence to medication has been reported to be 
prevalent in populations with CVD. However it should be noted 
that there is a variability in the evaluation methods (self-report, 
data of acquiring medication from the pharmacy and pill 
counts), which prevents the comparisons between studies and 
between different cardiovascular conditions.16,18 Also the 
cultural differences, age, chronic condition and the origin of 
the studied population are some of the factors which may 
determine the variation between the rates of non-adherence.
Future research should respond to important factors such 
as quality of life, coping mechanisms, self-efficacy, 
intervention programs at multidimensional level, analysis of 
their cost-beneÀ t and others that were not studied in this 
investigation.
Table 2 Multiple regression between treatment adherence and beliefs about medicines
CoefÀ cients F (P) t P R (R2)
 B b     
Constant 5.329   57.582 .000
SpeciÀ c concerns î0.039 î0.367 39.274 (.000) î6.267 .000* 0.367 (0.135)
* p < .05.
Patients’ beliefs about medicines and adherence to medication in ischemic heart disease 105
Adherence is characterized as a process of rational 
decision-making, which is driven by the beliefs and 
experiences of patients related to treatment and the 
disease. Several studies showed that the decision to adhere 
is exclusive to each medicine, and is driven by three factors, 
also known as the 3Cs - commitment, concerns and costs: 
a) the perception of the needs for medication (related to 
the understanding of disease and treatment); b) the 
perception relating to the concerns about medication 
(related to side effects and safety); and c) the perception of 
accessibility to medicines.10,11
The adherence results from a balance between the 
perception of the need to take medication and concerns 
about their adverse effects.
Improve adherence to medication is a highly effective 
strategy for better health outcomes, thereby obtaining 
better benefits in quality of life, than to invest in new 
medicines.19 In the cost-benefit analysis of adherence to 
medication, the estimates indicate that for every additional 
dollar spent on adherence the costs would decrease by 
7 dollars in diabetics, 5.10 in patients with hyperlipidemia 
and 3.98 in patients with hypertension.2,7
The nurses because of their intervention, the intensity of 
the relationship with the patient and their families, the 
informality that characterizes their interactions, which is 
highly valued by them, have a privileged space for inter-
vention in the context of multidisciplinary performance.
Thus, the behaviour changes in health require a number of 
strategies that depend on the level of knowledge of people 
regarding their health, their beliefs, their behaviours, their 
confidence levels, the strength of their social support 
networks, their levels of motivation and environmental 
factors.
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